Melanoma of Skin
9
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
APA (Adapted Physical Activity) for Patients With Advanced Melanoma
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.
An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.
MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)
Survivorship Promotion In Reducing IGF-1 Trial